• Home
  •  / Capricor Therapeutics

Capricor Therapeutics

  • Revenue$244.9 KFY, 2021
  • Market Capitalization$111.3 M2022-07-29

OverviewSuggest Edit

Capricor Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics for the treatment of diseases. Its lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. As a developer of innovative therapies, Capricor Therapeutics is strategically positioned at the forefront of one of the largest segments of the U.S. healthcare industry − cardiovascular disease.
TypePublic
Founded2005
HQBeverly Hills, CA, USMap
Websitecapricor.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)18(-53%)
Revenue (FY, 2021)$244.9 K(-21%)
Share Price (Jul 2022)$4.6(+2%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Capricor Therapeutics

Linda Marban

Linda Marban

President, Chief Executive Officer and Director
Karen Krasney

Karen Krasney

Executive Vice President and General Counsel
Anthony Bergmann

Anthony Bergmann

Chief Financial Officer
Kristi A H Elliott

Kristi A H Elliott

Vice President of Research and Development
Daniel Paulson

Daniel Paulson

Vice President of Clinical Development
Yasmine Shad

Yasmine Shad

Vice President of Quality
Show more

Capricor Therapeutics Office Locations

Capricor Therapeutics has an office in Beverly Hills
Beverly Hills, CA, US (HQ)
8840 Wilshire Blvd
Show all (1)

Capricor Therapeutics Financials and Metrics

Capricor Therapeutics Revenue

Capricor Therapeutics's revenue was reported to be $244.9 k in FY, 2021
USD

Net income (Q1, 2022)

(7.8m)

EBIT (Q1, 2022)

(7.8m)

Market capitalization (29-Jul-2022)

111.3m

Closing stock price (29-Jul-2022)

4.6

Cash (31-Mar-2022)

58.3m
Capricor Therapeutics's current market capitalization is $111.3 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Revenue

1.4m195.5k503.2k4.8m5.5m4.0m2.7m1.7m1.0m310.3k244.9k

Revenue growth, %

851%15%(28%)

General and administrative expense

2.1m1.6m2.2m3.0m4.4m4.9m4.8m4.9m3.6m5.5m7.6m

R&D expense

4.1m1.0m5.2m7.8m13.8m16.0m10.8m12.1m5.1m8.5m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Revenue

346.0k813.0k195.5k1.0m1.0m1.3m1.8m1.3m1.3m1.2m1.1m746.8k880.8k996.5k313.3k400.1k404.0k219.2k230.5k410.4k142.1k185.7k49.9k40.8k204.1k

General and administrative expense

523.3k499.3k500.0k442.0k397.2k262.5k384.6k852.3k665.7k819.7k1.4m926.3k972.8k1.1m1.4m1.3m1.2m1.2m1.1m1.4m1.2m1.3m976.5k831.9k912.0k1.1m1.6m1.9m1.8m1.8m2.7m

R&D expense

702.9k1.5m465.4k332.5k179.1k62.6k36.5k1.4m1.9m2.0m3.8m3.4m3.2m4.3m4.3m4.7m3.3m3.1m1.9m2.7m3.4m3.1m1.8m1.6m1.2m1.9m3.3m

Operating expense total

1.2m2.0m965.4k774.4k576.3k325.1k421.1k2.2m2.5m2.8m5.2m4.4m4.2m5.4m5.7m6.0m4.4m4.4m3.0m4.1m4.6m4.4m2.8m2.5m912.0k2.3m3.5m5.2m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Cash

1.0m46.7k1.7m8.0m5.6m3.2m6.1m4.3m3.9m32.7m34.9m

Accounts Receivable

Prepaid Expenses

271.3k124.9k222.8k235.5k210.6k501.2k724.2k571.4k1.0m1.2m

Inventories

342.9k
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Cash

3.3m2.6m435.7k777.2k282.5k285.0k229.2k71.0k13.0m11.6m9.8m6.9m5.0m4.2m11.8m8.9m18.0m2.8m8.3m8.9m7.2m6.3m4.4m7.2m5.9m6.8m13.2m36.3m41.9m38.1m40.8m58.3m

Prepaid Expenses

379.9k420.7k220.4k164.7k155.8k112.7k60.1k38.0k169.6k123.1k105.1k203.0k130.7k92.5k321.4k239.3k118.2k398.2k239.3k190.3k522.3k388.1k426.4k425.9k375.4k129.2k434.0k249.9k736.4k653.3k278.9k943.2k

Current Assets

3.6m3.0m656.1k941.8k438.3k404.3k289.3k109.0k14.0m16.4m14.2m25.4m21.6m17.7m14.9m11.8m22.4m13.5m13.6m15.2m14.6m13.5m11.4m7.9m6.6m7.3m13.8m36.6m42.6m38.7m41.3m59.6m

PP&E

12.7k10.9k8.0k6.4k4.9k1.2k994.0828.0163.5k204.0k224.5k253.8k263.1k332.1k345.0k355.3k351.5k411.9k399.0k394.0k535.2k507.4k622.3k541.7k506.7k474.7k410.9k486.8k838.7k1.1m1.5m2.3m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Net Income

(4.9m)(1.9m)(8.9m)(6.2m)(12.9m)(18.8m)2.4m(15.2m)(7.6m)(13.7m)(20.0m)

Depreciation and Amortization

7.5k6.3k26.9k41.9k110.9k125.7k144.2k157.7k172.0k143.9k245.7k

Accounts Payable

105.5k(254.9k)974.7k70.3k831.2k508.3k(1.5m)(347.4k)(273.2k)1.8m400.8k

Cash From Operating Activities

(4.6m)(2.2m)(6.1m)958.6k(10.8m)(15.8m)(14.2m)(13.9m)(6.8m)(10.1m)(16.8m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Net Income

(2.1m)(3.2m)(771.9k)(1.1m)(1.7m)(482.8k)(1.1m)(1.4m)(1.2m)(2.7m)(4.3m)(3.5m)(6.6m)(9.5m)(4.3m)(9.0m)(14.3m)(3.7m)(7.1m)(9.9m)(3.7m)(7.8m)(11.9m)(2.5m)(4.6m)(6.2m)(2.1m)(5.6m)(5.2m)(9.9m)(13.8m)(7.8m)

Depreciation and Amortization

4.1k5.9k1.8k3.4k4.8k1.0k1.2k1.4k6.5k16.2k28.4k24.8k51.0k79.8k31.6k65.1k91.8k38.8k76.1k109.6k34.1k73.0k114.4k43.3k86.4k129.2k33.0k65.6k50.1k102.3k167.1k92.5k

Accounts Payable

(94.6k)172.0k(110.7k)(316.1k)(227.8k)66.4k214.7k156.3k12.1k176.8k106.6k1.0m979.6k609.4k693.5k393.1k1.4m(533.0k)(861.0k)(1.8m)(87.9k)(289.9k)247.5k314.0k371.7k(201.2k)420.6k879.6k744.6k449.1k263.7k407.2k

Cash From Operating Activities

(2.4m)(3.1m)(603.5k)(1.5m)(2.0m)(144.2k)(200.0k)(358.2k)11.3m5.3m3.1m(2.1m)(3.9m)(7.2m)(4.2m)(9.1m)(11.6m)(4.7m)(8.4m)(11.6m)(3.4m)(7.1m)(10.1m)(1.6m)(3.4m)(5.0m)(1.2m)(3.2m)(3.3m)(7.8m)(11.2m)24.0m
show all
USDQ2, 2011

Financial Leverage

1.1 x
Show all financial metrics

Capricor Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

Learn more about our premium products
SecurityScorecard logo

Capricor Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Capricor Therapeutics Online and Social Media Presence

Capricor Therapeutics's Trends

Embed Graph

Capricor Therapeutics Company Culture

  • CEO Rating

    F

    10/100

Learn more on Comparably

Capricor Therapeutics News and Updates

July 19, 2022

Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy

-Double-Blind, Randomized, Placebo-Controlled HOPE-3 Clinical Trial Designed to Enroll approximately 70 Patients-
June 27, 2022

Capricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study

-Met Primary Endpoint of Performance of the Upper Limb PUL 2.0 (p=0.02)-
June 17, 2022

Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference

Results to be Presented in Late-Breaking Session Results to be Presented in Late-Breaking Session
May 25, 2022

Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer

Capricor Expands Senior Management Team to Build Commercial Strategy for Lead Asset, CAP-1002, and Further Develop Partnering Strategy for Proprietary Exosome Platform
May 18, 2022

Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference

SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Marbán, CEO of…
May 03, 2022

Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10

Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET
Show more

 Capricor Therapeutics Frequently Asked Questions

  • When was Capricor Therapeutics founded?

    Capricor Therapeutics was founded in 2005.

  • Who are Capricor Therapeutics key executives?

    Capricor Therapeutics's key executives are Linda Marban, Karen Krasney and Anthony Bergmann.

  • How many employees does Capricor Therapeutics have?

    Capricor Therapeutics has 18 employees.

  • What is Capricor Therapeutics revenue?

    Latest Capricor Therapeutics annual revenue is $244.9 k.

  • What is Capricor Therapeutics revenue per employee?

    Latest Capricor Therapeutics revenue per employee is $13.6 k.

  • Who are Capricor Therapeutics competitors?

    Competitors of Capricor Therapeutics include Keros Therapeutics, 19Labs and Palleon Pharmaceuticals.

  • Where is Capricor Therapeutics headquarters?

    Capricor Therapeutics headquarters is located at 8840 Wilshire Blvd, Beverly Hills.

  • Where are Capricor Therapeutics offices?

    Capricor Therapeutics has an office in Beverly Hills.

  • How many offices does Capricor Therapeutics have?

    Capricor Therapeutics has 1 office.